Rodríguez Cruz Yamila, Strehaiano Manon, Rodríguez Obaya Teresita, García Rodríguez Julío César, Maurice Tangui
Department of Histology, Institute of Preclinical and Basic Sciences, University of Medical Sciences, Havana, Cuba.
Center of Molecular Immunology (CIM), Havana, Cuba.
J Alzheimers Dis. 2017;55(1):231-248. doi: 10.3233/JAD-160500.
Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain, particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We previously reported the neuroprotective effect of a low sialic form of EPO, Neuro-EPO, applied intranasally in rodent models of stroke or cerebellar ataxia and in a non-transgenic mouse model of Alzheimer's disease (AD). Here we analyzed the protective effect of Neuro-EPO in APPSwe mice, a reference transgenic mouse model of AD. Mice were administered 3 times a day, 3 days in the week with Neuro-EPO (125, 250 μg/kg) intranasally, between 12 and 14 months of age. Motor responses, general activity, and memory responses were analyzed during and after treatment. The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APPSwe mice were alleviated by the low dose of Neuro-EPO. Oxidative stress, neuroinflammation, trophic factor levels, and a synaptic marker were analyzed in the hippocampus or cortex of the animals. The increases in lipid peroxidation or in GFAP and Iba-1 contents in APPSwe mice were significantly reduced after Neuro-EPO. Activation of intrinsic and extrinsic apoptotic pathways was analyzed. The increases in Bax/Bcl-2 ratio, TNFα, or Fas ligand levels observed in APPSwe mice were reduced by Neuro-EPO. Finally, immunohistochemical and ELISA analyses of Aβ1-42 levels in the APPSwe mouse cortex and hippocampus showed a marked reduction in Aβ deposits and in soluble and insoluble Aβ1-42 forms. This study therefore confirmed the neuroprotective activity of EPO, particularly for an intranasally deliverable formulation, devoid of erythropoietic side effects, in a transgenic mouse model of AD. Neuro-EPO alleviated memory alterations, oxidative stress, neuroinflammation, apoptosis induction, and amyloid load in 14-month-old APPSwe mice.
促红细胞生成素(EPO)是一种细胞因子,已知其在大脑中具有有效的细胞保护作用,尤其是在缺血、创伤、炎症和神经退行性疾病中。我们之前报道了低唾液酸形式的EPO(神经EPO)经鼻给药在中风或小脑共济失调的啮齿动物模型以及阿尔茨海默病(AD)的非转基因小鼠模型中的神经保护作用。在此,我们分析了神经EPO在AD的参考转基因小鼠模型APPSwe小鼠中的保护作用。在12至14月龄期间,给小鼠每天经鼻给予神经EPO(125、250μg/kg)3次,每周3天。在治疗期间和治疗后分析运动反应、一般活动和记忆反应。低剂量的神经EPO减轻了APPSwe小鼠中观察到的自发交替、水迷宫中的位置学习和新物体识别缺陷。分析了动物海马体或皮质中的氧化应激、神经炎症、营养因子水平和突触标记物。神经EPO处理后,APPSwe小鼠中脂质过氧化或GFAP和Iba-1含量的增加显著降低。分析了内源性和外源性凋亡途径的激活情况。神经EPO降低了APPSwe小鼠中观察到的Bax/Bcl-2比值、TNFα或Fas配体水平的增加。最后,对APPSwe小鼠皮质和海马体中Aβ1-42水平的免疫组织化学和ELISA分析显示,Aβ沉积物以及可溶性和不溶性Aβ1-42形式显著减少。因此,本研究证实了EPO的神经保护活性,特别是对于一种经鼻给药的制剂,其在AD转基因小鼠模型中没有促红细胞生成的副作用。神经EPO减轻了14月龄APPSwe小鼠的记忆改变、氧化应激、神经炎症、凋亡诱导和淀粉样蛋白负荷。